Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review

References

• Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19(suppl_5):v1–v88. doi:10.1093/neuonc/nox158.
   PubMed Web of Science ®Google Scholar
• Fathi AR, Roelcke U. Meningioma. Curr Neurol Neurosci Rep. 2013;13(4):337. doi:10.1007/s11910-013-0337-4.
   PubMed Web of Science ®Google Scholar
• System Tumors. 2016 World Health Organization classification of central nervous. Continuum (Minneap Minn). 2017;23(6,Neuro–oncology):1531–1547. doi:10.1212/CON.0000000000000536.
   PubMedGoogle Scholar
• Le Rhun E, Taillibert S, Chamberlain MC. Systemic therapy for recurrent meningioma. Expert Rev Neurother. 2016;16(8):889–901. doi:10.1080/14737175.2016.1184087.
   PubMed Web of Science ®Google Scholar
• Caruso G, Elbabaa SK, Gonzalez-Lopez P, Barresi V, Passalacqua M, Caffo M. Innovative therapeutic strategies in the treatment of meningioma. Anticancer Res. 2015;35(12):6391–6400.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomidefor treatment-resistant recurrentmeningioma. Neurology. 2004 13;62(7):1210–1212. doi:10.1212/01.WNL.0000118300.82017.F4.
   PubMed Web of Science ®Google Scholar
• Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16(6):829–840. doi:10.1093/neuonc/not330.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3):271–276. doi:10.1007/s11060-005-9093-x.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996 May;84(5):733–736. doi:10.3171/jns.1996.84.5.0733.
   PubMed Web of Science ®Google Scholar
• Cea-Soriano L, Blenk T, Wallander MA, Rodríguez LA. Hormonal therapies and meningioma: is there a link? Cancer Epidemiol. 2012;36(2):198–205. doi:10.1016/j.canep.2011.08.003.
   PubMed Web of Science ®Google Scholar
• Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WKA, Gilbert MR, Fine HA, Mehta M, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–217. doi:10.1007/s11060-009-9948-7.
   PubMed Web of Science ®Google Scholar
• Karaman S, Leppänen VM, Alitalo K. Vascular endothelial growth factor signaling in development and disease. Development. 2018;145:14. doi:10.1242/dev.151019.
   Web of Science ®Google Scholar
• Kampmann E, Altendorf-Hofmann A, Gibis S, Lindner LH, Issels R, Kirchner T, Knösel T. VEGFR2 predicts decreased patients survival in soft tissue sarcomas. Pathol Res Pract. 2015;211(10):726–730. doi:10.1016/j.prp.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Nakada S, Sasagawa Y, Tachibana O, Iizuka H, Kurose N, Shioya A, Guo X, Yamada S, Nojima T. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival. Brain Tumor Pathol. 2019;36(1):7–13. doi:10.1007/s10014-018-0332-1.
   PubMed Web of Science ®Google Scholar
• Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. Dan Med J. 2013;60(4):B4626. Review.
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116–121. doi:10.1093/neuonc/nou148.
   PubMed Web of Science ®Google Scholar
• Lou E, Ashley L, Sumrall ST, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63–70. doi:10.1007/s11060-012-0861-0.
   Google Scholar
• Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015;51(4):223–229. doi:10.1358/dot.2015.51.4.2320599.
   PubMed Web of Science ®Google Scholar
• Xichun H, Cao J, Wenwei H, Changping W, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, et al. Multicenter phase II study ofApatinibin non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. doi:10.1186/1471-2407-14-820.
   PubMed Web of Science ®Google Scholar
• Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, et al. Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol. 2016;10(8):887–892.
   PubMed Web of Science ®Google Scholar
• Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinibfor advanced sarcoma: results from multiple institutions’ off-label use in China. BMC Cancer. 2018;18:396. doi:10.1186/s12885-018-4303-z.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, double-blind, placebo-controlled phase III trial ofapatinibin patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, Rice L, McCarthy K, Johnston SK, Mrugala MM, et al. A phase II trial of PTK787/ZK222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014;117(1):93–101. doi:10.1007/s11060-014-1358-9.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–193. doi:10.1007/s11060-012-0886-4.
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380. doi:10.1111/cas.2011.102.issue-7.
   PubMed Web of Science ®Google Scholar